Alerta

LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF

Resumen de: WO2025117816A1

Disclosed herein are lipid nanoparticles (LNPS) and pharmaceutical compositions and vaccines comprising same. Also disclosed herein are methods of administering an LNP composition, pharmaceutical compositions, and vaccines described herein for preventing an infectious disease and/or for immunizing a subject or for delivering a payload to a cell in the central nervous system (CNS) of a subject. Also provided are methods for treating and/or preventing a CNS disease.

SUPPLEMENTATION OF LIVER ENZYME EXPRESSION

Resumen de: WO2025117858A1

Described herein are methods, compositions, and systems derived from uncultivated microorganisms useful supplementing liver enzyme deficiencies.

OXIDATION-RESPONSIVE CATIONIC WATER-SOLUBLE PILLARARENE, AND PREPARATION METHOD AND USE

Resumen de: EP4818181A1

Disclosed are an oxidation-responsive water-soluble cationic pillararene, and a preparation method and application thereof, the oxidation-responsive water-soluble cationic pillararene is a cyclic small-molecule nucleic acid vector, and is obtained by quaternization reaction of 4-methylborate and tertiary amine-modified pillararene. According to the invention, a delivery vector with a high positive charge density is obtained through small molecule synthesis, the delivery vector is capable of being tightly combined with negatively charged nucleic acid substances to form a nano-composite, and after the nano-composite enters cells, vector positive charges fall off to release the nucleic acid substances in an oxidation environment, and nucleic acid information is efficiently expressed. The delivery vector has the characteristics of simplicity and convenience in synthesis, high delivery efficiency and good biological safety, and has a good application prospect.

BIFUNCTIONAL COMPOSITE MOLECULE OF ANTI-TUMOR ANTIBODY AND INTERLEUKIN-15 PRECURSOR, AND USE OF BIFUNCTIONAL COMPOSITE MOLECULE

Resumen de: EP4818212A1

0001 The present inventions provides a complex molecule, a nucleic acid, a vector, a host cell, and a pharmaceutical composition, and use thereof in the manufacture of a medicament for treating cancer. The complex molecule comprises an antitumor antibody domain, a linker, and pro-IL-15, wherein the antitumor antibody domain and pro-IL-15 are linked by the linker. The antitumor antibody domain is a complete antibody, a nanobody, or an antigen-binding fragment thereof against an immune checkpoint molecule, a tumor antigen molecule, or an immune activation molecule. The linker is a polypeptide linker or a non-peptide linker. The pro-IL-15 is a fusion protein comprising IL-15, an IL-15Rα sushi domain, a linking peptide, and optionally an IL-15Rβ extracellular domain, wherein the IL-15Rβ extracellular domain, IL-15, and the IL-15Rα sushi domain are linked by linking peptides.

COMPOUND COMPRISING EXTRACELLULAR VESICLES DERIVED FROM BIOLOGICAL MATERIAL NOT BELONGING TO THE ANIMAL KINGDOM AND ITS APPLICATIONS

Resumen de: WO2025114909A1

Compound for relieving inflammation in an organism comprising nanometer-sized extracellular vesicles (EVs) derived from biological material not belonging to the animal kingdom, but preferably belonging to the plant and fungi kingdoms, and loaded with a bioactive or a mixture of bioactives, preferably of plant origin.

CANNABIS COMPOSITIONS, ORAL PRODUCTS, AND METHODS OF MAKING SAME

Resumen de: US12263241B1

The disclosed technology includes cannabinoid oral products, and methods for making same. In some embodiments, the oral products are pouches including cannabinoid infused wafers. In some embodiments, the method of making the cannabinoid oral products includes preparing an emulsion, preparing a spray dry solution, spray drying solution into cannabinoid and carbohydrate particles, preparing a paste, preparing a wafer in a heated vacuum oven, fragmenting the wafer into cannabinoid infused wafer fragments, mixing the cannabinoid infused wafer fragments with starch, and dispensing the cannabinoid infused wafer fragments into pouches. The methods may also include labeling the oral products, for example, with a THC warning symbol.

NANOPARTICLES COMPRISING SIROLIMUS AND ALBUMIN, PHARMACEUTICAL COMPOSITION FOR SUBCUTANEOUS ADMINISTRATION, COMPRISING SAME, AND PREPARATION METHOD THEREFOR

Resumen de: EP4817601A1

The present disclosure relates to nanoparticles comprising sirolimus and albumin, a pharmaceutical composition for subcutaneous administration comprising the same, and a method for preparing the same. When the preparation method of the present disclosure is used, nanoparticles comprising sirolimus and albumin having excellent particle size distribution maintenance stability can be prepared, and the prepared nanoparticles can be prepared into a pharmaceutical composition suitable for subcutaneous injection, thereby improving an increase in an administration dose and the convenience of medication administration.

HYBRID PARTICLES COMPRISING A CROSS-LINKED POLYSACCHARIDE MATRIX AND METAL OXIDE NANOPARTICLES

Resumen de: WO2025114612A1

Hybrid particles comprising a cross-linked polysaccharide matrix and metal oxide nanoparticles The invention relates to a method of manufacturing hybrid particles comprising a matrix of cross-linked polysaccharide and metal oxide nanoparticles embedded therein. It has been found that hybrid particles with low polydispersity and a high load of metal oxide nanoparticles could be obtained when non-coated metal oxide nanoparticles are used. Aggregation of the non-coated metal oxide nanoparticles could be controlled to achieve said polydispersity and load. The hybrid particles of the invention, when the metal oxide is a magnetic and photothermal metal oxide, could act on the thrombosis via a combination of thermal and mechanical action, through light and magnetic stimulation, and would be targeted to the occluded vessel by an external permanent magnet.

IONIZABLE LIPID NANOPARTICLES

Resumen de: WO2025114520A1

The present invention relates to ionizable lipid nanoparticles (LNPs) including at least one lipid molecule comprising a thiourea moiety linked to a functional moiety. The ionizable lipid nanoparticles (LNPs) including at least one lipid molecule comprising a thiourea moiety linked to a functional moiety, disclosed herein, are useful in delivering an agent to a cell or in transfecting a cell, especially for gene therapy or for gene editing.

CROSSLINKED POLYSACCHARIDE NANOPARTICLES

Resumen de: WO2025114613A1

Crosslinked polysaccharide nanoparticles The present invention relates to cross-linked polysaccharide nanoparticles, which can be used as drug delivery systems. The herein disclosed cross-linked polysaccharide nanoparticles are obtained via an emulsion cross-linking process. The careful choice of the surfactants used for forming the emulsion allows to reliably obtain small particles with a low polydispersity. Moreover, these particles are stable in saline solutions. The cross-linked polysaccharide nanoparticles can be loaded with proteinaceous fibrinolytic or thrombolytic agents and could be used as drug delivery systems for the treatment of thrombosis.

GLUCOSE-TRIGGERED GELATION OF SUPRAMOLECULAR PEPTIDE NANOCOILS WITH GLUCOSE-BINDING MOTIFS

Resumen de: WO2025117822A1

Described herein are self-assembled peptides and hydrogels comprising self-assembled peptides and glucose. Exemplary hydrogels comprising self-assembled peptides and glucose may be used to encapsulate glucagon and/or a glucagon analogue. Hydrogels with glucagon and/or a glucagon analogue encapsulated therein may be used to treat hypoglycemia and related disorders in subjects in need thereof.

RADIOPAQUE NANOPARTICLES FOR MEDICAL IMAGING

Resumen de: US20250177577A1

The present disclosure features imaging media including a contrast agent encapsulated within a biodegradable nanoparticle matrix. The particles are sized such that they avoid excretion via urinary excretion (e.g., at least 5 nm in diameter) during an imaging procedure or an image-guided procedure. Instead, the particles are predominantly removed from circulation by the reticuloendothelial system of the liver. This results in a buildup of contrast agent in the liver, allowing for a highly specific imaging modality for liver imaging. Further, the bulk of the imaging media is excreted into the bowel, reducing in-vivo toxicity of the imaging media. Finally, because of their size, the nanoparticles of the imaging media have a higher circulation half-life.

PROCESS FOR MANUFACTURING LIPID NANOPARTICLES

Resumen de: WO2025117969A1

The present application provides methods for manufacturing lipid nanoparticles. The present disclosure provides methods of preparing empty lipid nanoparticles (empty LNPs). The present disclosure provides methods of preparing loaded lipid nanoparticles (loaded LNPs) associated with a nucleic acid. Empty and loaded LNP compositions prepared by the subject methods are also provided. There is provided a homogeneous LNP composition of empty or loaded LNPs of particularly favorable average particle size and poly dispersity index.

LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF

Resumen de: WO2025117817A1

Provided are aerosolized pharmaceutical compositions including comprising aerosol particles, the aerosol particles comprising lipid nanoparticles (LNPs), the LNP comprising at least two selective organ targeting (SORT) lipids and/or at least six lipids. Also provided herein are methods of administering the aerosolized pharmaceutical compositions described herein.

METHOD OF ENCAPSULATING MYCOBACTERIUM BOVIS BCG VACCINE BACILLI IN AN ALGINATE CARRIER TO COMBAT HELICOBACTER PYLORI INFECTION

Resumen de: EP4817599A1

0001 The invention relates to a method of manufacturing microparticles containing Mycobacterium bovis BCG vaccine bacilli encapsulated in an alginate carrier, intended for combating Helicobacter pylori infection, characterised in that an aqueous solution of a non-ionic copolymeric surfactant (C<3>H<6>O.C<2>H<4>O) and/or a solution of chitosan in 1% acetic acid, and a suspension of live M. bovis BCG in 1 mL of saline solution with a BCG density of 3×10<9> CFU/mL, and then subjected to a microencapsulation procedure by adding the above-mentioned solutions dropwise, using a 2 mL syringe, to a vessel containing a 0.5% calcium chloride solution, at room temperature on a magnetic stirrer for 1 hour. After one hour, the microcapsules are drained using a laboratory sieve and rinsed with sterile distilled water, using chitosans with a molecular weight in the range of 50.000-190.000 g/mol or 190.000-310.000 g/mol or 310.000-375.000 g/mol, with the concentration of the polymer solution used to prepare the alginate microcapsules being 2% v/v for alginate, 1% v/v for chitosan and 12 600 g/mol for the non-ionic copolymer surfactant (C<3>H<6>O.C<2>H<4>O)x.

LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF AND METHOD FOR QUANTIFYING AN AMOUNT OF CAPPED MESSENGER RNA

Resumen de: WO2025117815A1

Provided are lipid nanoparticles compositions comprising a payload, a helper lipid, a sterol, a PEG-lipid, an ionizable lipid, a permanently cationic lipids. Also provided herein are a method of delivering a payload to a cell in a lung of a subject by intravenous administration and a method for treating and/or preventing a lung disease in a subject in need thereof by intravenous administration. Also provided are a method for quantifying an amount of capped messenger RNA (mRNA) in an mRNA sample comprising contacting the mRNA with two or more of a nuclease, an alkaline phosphatase, and a polynucleotide kinase and separating the capped mRNA and the uncapped mRNA occurs using chromatography.

一种表面生长无机钙壳层的锰基金属有机框架药物载体及其制备方法和抗肿瘤应用

Resumen de: CN122849191A

本发明涉及生物材料技术领域，特别是涉及一种表面生长无机钙壳层的锰基金属有机框架药物载体及其制备方法和抗肿瘤应用。本发明利用无机钙壳层提升载体体内安全性与肿瘤靶向能力，稳定优化药物体内药代动力学特征，实现化疗药物与功能性锰离子安全长效共递送。载体富集至肿瘤微环境后，可依托酸性微环境特异性逐层降解释药，同步介导化学动力学治疗、激活机体内源抗肿瘤免疫通路，多元联动实现高效协同抑瘤。最终确立一类生物相容性佳、活体安全性高的新型肿瘤协同锰疗法。

一种仿生细菌囊泡制剂及其制备方法和应用

Resumen de: CN122849193A

本发明公开了一种仿生细菌囊泡制剂，包括表面修饰有脲酶和叶酸的细菌囊泡和负载于所述细菌囊泡中的活性成分，其中，所述活性成分为级联多酶体系或者治疗性核酸分子。本发明在双歧杆菌囊泡表面修饰脲酶结构，能够催化尿素产生NH3和CO2，NH3中和胃酸防止囊泡降解，而CO2为囊泡的运动提供了微动力。进一步，通过脂质‑叶酸偶联物修饰囊泡，赋予了细菌囊泡靶向小肠的功能。口服给药后，包封在囊泡内的β‑半乳糖苷酶、半乳糖氧化酶和过氧化氢酶发生时空耦合的级联反应，促进乳糖及其中间产物半乳糖和过氧化氢的快速降解，从而对乳糖不耐受产生良好的治疗效果。所述仿生囊泡平台还兼具递送不同mRNA的潜力，为代谢性疾病的治疗提供了一种新方案。

一种石墨烯远红外消炎镇痛贴及其制备方法

Resumen de: CN122849004A

本发明公开了一种石墨烯远红外消炎镇痛贴及其制备方法，包括膏体和基布，膏体由膏体基质和分散于其中的功能性微囊组成；功能性微囊包含芯材和壁材，芯材为石墨烯量子点与纳米级远红外陶瓷粉的复合物，壁材为多孔聚乳酸‑羟基乙酸共聚物；膏体基质由包括如下质量份数的组分制备而成：多孔石墨烯气凝胶2~5份、功能性微囊10~25份、热熔胶60~80份、渗透促进剂2~5份、挥发油组分3~10份；多孔石墨烯气凝胶的孔径分布为50~200nm，比表面积为300~600m²/g，且其表面接枝有亲水性羧基和疏水性烷基链，形成两亲性表面结构；将多孔石墨烯气凝胶与功能性微囊复合应用于消炎镇痛贴中，作为高效的导热骨架和远红外辐射增强基体，显著提升热量在膏体层中的传导速率和分布均匀性。

黄芩苷靶向纳米粒及其制备方法和用途

Resumen de: CN122849190A

本申请实施例提供了一种黄芩苷靶向纳米粒及其制备方法和用途，涉及生物医药技术领域。本申请实施例的黄芩苷靶向纳米粒包括聚乳酸‑羟基乙酸共聚物基质和脂质组合物，所述聚乳酸‑羟基乙酸共聚物基质中分散包埋有黄芩苷和油酸修饰超顺磁性四氧化三铁纳米粒；所述脂质组合物分布于聚乳酸‑羟基乙酸共聚物基质的表面；所述脂质组合物包括大豆磷脂和二硬脂酰磷脂酰乙醇胺‑聚乙二醇2000。本实施例构建的聚合物‑脂质杂合纳米粒能有效改善黄芩苷水溶性差及稳定性弱的理化缺陷，同时实现纳米粒体内长循环、高细胞摄取、磁场定向肿瘤富集多重性能，显著提升黄芩苷肿瘤靶向递送效率，进而有效改善抗肿瘤治疗效果。

ＲＮＡコンストラクトおよびその使用

Resumen de: CN113521269A

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

一种肺炎支原体多价mRNA疫苗及其制备方法和应用

Resumen de: CN122849427A

本发明公开了一种肺炎支原体多价mRNA疫苗及其制备方法和应用，涉及生物医药技术领域。所述疫苗包括编码肺炎支原体抗原的mRNA分子和荷载所述mRNA分子的脂质纳米颗粒；所述肺炎支原体抗原为P1抗原片段、P30抗原片段、P116抗原片段和CARDS抗原片段及其组合；所述P1抗原片段的氨基酸序列如SEQ ID NO：1所示；所述P30抗原片段的氨基酸序列如SEQ ID NO：2所示；所述P116抗原片段的氨基酸序列如SEQ ID NO：3所示；所述CARDS抗原片段的氨基酸序列如SEQ ID NO：4所示。本发明采用非核苷酸修饰的mRNA技术路线，通过序列优化和低dsRNA副产物T7 RNA聚合酶突变体合成策略，在实现高效翻译表达的同时，避免了非预期移码错译蛋白的产生和潜在的脱靶免疫应答，使疫苗更加安全可靠。

一种分阶段实现溶酶体规避与靶向的载药脑部递送载体及其应用

Resumen de: CN122849186A

本发明公开了一种分阶段实现溶酶体规避与靶向的载药脑部递送载体，其以叶酸修饰的聚合物纳米材料为载药内核，以膜融合脂质体与人脑微血管内皮细胞膜融合形成的仿生杂化膜为包覆层。该载药脑部递送载体跨越血脑屏障时，可通过膜融合机制规避传统溶酶体胞内转运途径，有效避免药物载体在脑微血管内皮细胞内发生溶酶体滞留与降解，保障载药内核高效穿透脑部血管抵达脑实质；随后，载药内核可借助表面特异性配体叶酸精准靶向脑肿瘤细胞，并于其溶酶体内释放药物，一方面有效削弱肿瘤细胞溶酶体的细胞保护效应，另一方面可直接破坏肿瘤细胞溶酶体，引发其功能紊乱和内容物外泄，诱导肿瘤细胞死亡，从多维度显著提升脑肿瘤治疗效果。

一种两性离子聚合物及包含其的脂质组合物和用途

Resumen de: CN122854573A

本公开涉及靶向递送脂质技术领域，具体涉及一种两性离子聚合物及包含其的脂质组合物和用途。本公开提供的靶向脾的两性离子聚合物具有式(I)所示的结构，可用作RNA靶向递送，能够显著增强mRNA药物对于脾靶向效果。

一种眼后段药物递送的脂质体、包含脂质体的滴眼液及其应用

Nº publicación: CN122849159A 02/10/2026

Solicitante:

天津市眼科医院

Resumen de: CN122849159A

本申请涉及生物医药及创新制剂开发技术领域，具体涉及一种眼后段药物递送的脂质体、包含脂质体的滴眼液及其应用。所述脂质体包括脂质体内核和外层短肽修饰层，所述的脂质体内核包括脂质双层膜，所述短肽包括Gly‑Ser。所述脂质体内核中可以稳定包载治疗剂，将其制备为纳米滴眼液。所述的纳米滴眼液在不影响眼表屏障功能的基础上显著提升治疗剂的跨眼后段穿透性，并且显著提升对于眼病的治疗效果。